© 2000 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Trimetazidine: a novel protective role via maintenance of Na+/K+-ATPase activity?
Department of Pathology, Box 3712, Duke University Medical Center, Durham, NC 27710, USA
* Tel.: +1-919-541-5411; fax: +1-919-541-3385 laszlo.deszi@richter.hu
Received 14 June 2000; accepted 26 June 2000
| The first 10% of the full text of this article appears below. |
See article by El Banani et al. [31] (pages 688–696) in this issue.
Trimetazidine (1-[2,3,4-trimethoxybenzyl]-piperazine; TMZ) is a piperazine compound that has been demonstrated to protect against ischaemic injury in a variety of tissues [1–4]. As a cardiovascular therapeutic agent, TMZ is protective during coronary artery bypass graft surgery [5] and catheter angioplasty [6], has been effective in the treatment of angina [7,8] and reduces infarct size when given before thrombolysis in patients with anterior myocardial infarction [9]. There have been insights into some of the molecular mechanisms of action of TMZ, however, new mechanisms continue to be discovered [10–12]. The best known action of